Arzneimittel mit dem Wirkstoff Natalizumab (ATC: L04AG03)

TENDER DESCRIPTION

Conclusion of non-exclusive discount agreements in accordance with § 130a para. 8 SGB V for finished medicinal products containing the active ingredient Natalizumab (ATC: L04AG03) with the possibility of conclusion at any time within the framework of a so-called "open-house model." A contract will be concluded with each pharmaceutical company that meets the participation requirements. Exclusivity is not granted. Joining or concluding the contract can take place at any time and under the same conditions. Individual contract negotiations are not conducted. The earliest contract start date is 01.10.2026. Based on this, the contract duration is a maximum of 24 months. The contract ends on 30.09.2028 regardless of the contract start date. Should AOK Sachsen-Anhalt tender exclusive contracts for the active ingredients during the contract period in accordance with the applicable procurement law provisions, the contracts concluded within the scope of this publication will be terminated in accordance with the contractual regulations. This publication does not constitute the awarding of a public contract within the meaning of § 103 GWB or procurement law. To ensure the greatest possible…

TENDER BRIEF

TENDER DOCUMENTS